UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 15

 

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION
OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-35935

 

 

 

PORTOLA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

270 E. Grand Avenue

South San Francisco, California 94080

(650) 246-7000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, $0.001 Par Value

(Title of Class of Securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1) x
Rule 12g-4(a)(2) ¨
Rule 12h-3(b)(1)(i) x
Rule 12h-3(b)(1)(ii) ¨
Rule 15d-6 ¨
Rule 15d-22(b) ¨

 

Approximate number of holders of record as of the certification or notice date: One (1)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Portola Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

  PORTOLA PHARMACEUTICALS, INC.
   
Date:  July 13, 2020 By:  /s/ Aradhana Sarin                         
  Name: Aradhana Sarin
  Title: Director and President

 

 

 

 

Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
Von Okt 2024 bis Nov 2024 Click Here for more Portola Pharmaceuticals Charts.
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
Von Nov 2023 bis Nov 2024 Click Here for more Portola Pharmaceuticals Charts.